# OnCo record tmb-high (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/tmb-high/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "tmb-high" ;
  schema:name "TMB-high (tumour mutational burden >= 10 mutations per megabase)"@en ;
  schema:alternateName "TMB-H"@en, "TMB-high"@en, "TMB high"@en, "tumor mutational burden"@en, "tumour mutational burden"@en, "TMB >= 10 mut/Mb"@en, "TMB ≥10"@en, "TMB-H solid tumors"@en, "bTMB"@en, "blood TMB"@en ;
  schema:description "TMB counts how many mutations a tumour carries per million DNA letters. Ten or more, measured by FoundationOne CDx, allows pembrolizumab for almost any solid tumour after other treatment has failed."@en ;
  schema:url <https://onco.cc/biomarkers/tmb-high/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287> ;
  onco:tag "biomarker", "genome-wide" ;
  onco:related <https://onco.cc/biomarkers/msi-high/>, <https://onco.cc/biomarkers/dmmr-ihc/> ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/urothelial/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/foundationone-cdx/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/neoantigen/> .